In the good old days of the Cold War (well, old days at least) the Pentagon was a key driver of technological innovation, and its dominance was reflected in the structure of R&D and procurement programs. But the old bureaucracy is woefully unsuited to […]
Tag: R&D
Want to cure Alzheimer’s? Fix IP laws
The last few years have brought a slew of new treatments (and sometimes cures) for fatal and chronic diseases long considered almost untreatable, including various cancers, diabetes, and heart disease. But one foe has remained seemingly intractable: dementia associated with old age, particularly Alzheimer’s. […]
Ten years after crisis Europe is sort of the same, also worse
A decade after the global financial crisis and ensuing economic downturn, how has Europe changed? Well, not as much as you might expect, according to Matthew Edwards, writing for the Austrian Economics Center. Analyzing data from the OECD and Eurostat, Edwards finds surprisingly little difference from pre-crisis conditions… and unfortunately what has changed […]
EU jeopardizing innovation with IP threats
Philip Stevens, Executive Director, Geneva Network. The European Parliament in April voted through a proposal that will allow generic companies to manufacture and export outside the EU copies of medicines that are still essentially patent protected in Europe. This vote around what’s known as the Supplementary Protection Certificate (SPC) Export Waiver may […]
Protect IP or give up miracle cures yet uninvented
In a piece for the Morning Consult, Philip Thompson of the Property Rights Alliance highlights the importance of intellectual property in powering innovation, especially in key categories like medicine: Ja’Ceon Golden, a “bubble boy” cured with healthy genes delivered via a “hijacked” (and otherwise harmless) HIV virus, is a poster boy for medical innovation. […]
DELINKAGE: CAN PRIZES REPLACE PATENTS FOR MEDICINE INNOVATION?
By Philip Stevens, Executive Director, Geneva Network Republished with permission of the Geneva Network. Original available here. The patent-based system of drug development comes under further pressure from key countries aiming to increase access to medicines at a joint World Health Organization and Government of India meeting in New Delhi this week. […]
The market for antibiotics is a “disaster”
The Wellcome Trust’s Jeremy Farrar is all but begging for action to shore up the failing antibiotics market. Decades of weak investment in antibiotics has left “perilously few” companies involved in antibiotic development—a market crisis unfolding alongside the rise of deadly drug-resistant superbugs. Farrar warns that there is currently no viable pathway to market […]